sábado, 17 de febrero de 2018

BioEdge: First case report of transgender woman breastfeeding an infant

BioEdge: First case report of transgender woman breastfeeding an infant

Bioedge

First case report of transgender woman breastfeeding an infant
     
In another step forward in the transgender movement, a trans woman (a natal male) has been helped to breast-feed her partner’s baby.

The 30-year-old woman sought help from Mount Sinai’s Center for Transgender Medicine and Surgery in New York City. Her partner did not want to breastfeed and she wanted to assist. Although she had not had gender-reassignment surgery, after years of taking medication, she had well-developed breasts.

From chatter on internet forums, it appears that trans women are experimenting with drugs to help them lactate. This person took an anti-nausea drug called domperidone which is used off-label to trigger breast milk, in combination with feminising hormones oestrogen, progesterone and spironolactone.

As a result she was eventually producing 227 grams of breast milk a day. This is below the 500 grams that babies need so she had to supplement it with formula. The authors of the study in the journal Transgender Health concluded that “modest but functional lactation can be induced in transgender women”.

“This is a very big deal,” says Joshua Safer of Boston Medical Center, told New Scientist. “Many transgender women are looking to have as many of the experiences of non-transgender women as they can, so I can see this will be extremely popular.”

While this development was greeted with great enthusiasm, further studies are needed to ensure that it is safe. Domperidone is associated with cardiac arrhythmias, cardiac arrest, and sudden death when used intravenously. There are reports that spironolactone is associated with tumours in rats. There may be other, long term effects, such influencing the child’s IQ.


Bioedge

Saturday, February 17, 2018


Last year the London Telegraph ran a travel article about Belgium, “10 reasons why Belgium is not as boring as you think”. A bit patronising, right?
Personally, I’d never call a country which has dared to legalise euthanasia boring. Anything but. This is a defiant poke in the eye to hundreds of years of Western civilisation. Whether you agree with Belgium’s regime of legalised euthanasia or not, it is a wildly exciting experiment in disrupting established social norms.
The latest news is that a whistleblower has accused the country’s euthanasia commission of breaking the law, muzzling dissent, and packing the commission with euthanasia practitioners. In other countries this would be called corruption. The whistleblower's letter to the Belgian Parliament is a searing indictment of a respected institution. You would think that the Belgian media would be baying for blood.
Nope. It was an American news agency, Associated Press, which broke the story. As far as I can see, it has been reported around the world, but not in Belgium. It’s a funny kind of journalism which ignores such a big story.  Perhaps the media there believes that Belgium really is as boring as you think. Or perhaps they are in the pocket of the euthanasia lobby. 
Michael Cook
Editor
BioEdge


NEWS THIS WEEK
by Xavier Symons | Feb 17, 2018
But commission denies that there has been any negligence
 
 
by Xavier Symons | Feb 17, 2018
An increasingly number of desperate couples are descending on Ukraine. 
 
 
by Xavier Symons | Feb 17, 2018
Several former members of the Dallas Cowboys have received stem-cell therapy in Mexico. 
 
 
by Xavier Symons | Feb 17, 2018
Persons over the age of 18 must notify authorities if they don't want to donate. 
 
 
by Xavier Symons | Feb 17, 2018
The ACLU has launched a legal challenge against Ohio’s new down syndrome abortion law. 
 
 
by Michael Cook | Feb 16, 2018
Illegally sold to a sick businessman to settle a dowry
 
 
by Michael Cook | Feb 16, 2018
Last year, it helped 734 people to die 
 
 
by Michael Cook | Feb 16, 2018
Modest but functional lactation can be induced in transgender women
BioEdge
Phone: +61 2 8005 8605
Mobile: 0422-691-615

No hay comentarios: